Citadel Advisors
CNTA

Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Citadel Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8M Buy
598,197
+78,235
+15% +$2M ﹤0.01% 2123
2025
Q4 		$13M Buy
519,962
+382,761
+279% +$9.69M ﹤0.01% 2894
2025
Q3 		$3.33M Buy
+137,201
New +$2.44M ﹤0.01% 5122
2025
Q2 		– Sell
-706,331
Closed -$8.95M – 12833
2025
Q1 		$10.2M Buy
706,331
+81,015
+13% +$1.33M ﹤0.01% 2833
2024
Q4 		$10.5M Buy
625,316
+37,798
+6% +$626K ﹤0.01% 2928
2024
Q3 		$9.39M Buy
587,518
+549,242
+1,435% +$6.73M ﹤0.01% 2995
2024
Q2 		$346K Sell
38,276
-8,692
-19% -$82.4K ﹤0.01% 8862
2024
Q1 		$531K Sell
46,968
-53,836
-53% -$510K ﹤0.01% 8263
2023
Q4 		$802K Buy
100,804
+97,785
+3,239% +$656K ﹤0.01% 7124
2023
Q3 		$19.5K Sell
3,019
-1,086
-26% -$7.43K ﹤0.01% 12645
2023
Q2 		$25.4K Buy
+4,105
New +$19.5K ﹤0.01% 12526
2023
Q1 		– Sell
-72,307
Closed -$224K – 14806
2022
Q4 		$224K Sell
72,307
-153,061
-68% -$567K ﹤0.01% 9913
2022
Q3 		$906K Sell
225,368
-65,215
-22% -$298K ﹤0.01% 7207
2022
Q2 		$1.42M Sell
290,583
-13,843
-5% -$88.6K ﹤0.01% 6246
2022
Q1 		$2.73M Sell
304,426
-35,639
-10% -$325K ﹤0.01% 5399
2021
Q4 		$3.83M Sell
340,065
-9,483
-3% -$128K ﹤0.01% 4844
2021
Q3 		$5.84M Sell
349,548
-106,685
-23% -$2.21M ﹤0.01% 4015
2021
Q2 		$10.1M Buy
+456,233
New +$10.7M ﹤0.01% 3044

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citadel Advisors's CNTA Position: Q1 2026 in Review

Citadel Advisors increased its Centessa Pharmaceuticals (CNTA) stake by 15% in Q1 2026, buying an estimated $2M and bringing the position to 598,197 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Citadel Advisors first reported a position in CNTA in Q2 2021 and has held it in 18 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Citadel Advisors held 598,197 shares of Centessa Pharmaceuticals worth $23.8M as of Q1 2026.
  • Citadel Advisors bought 78,235 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Centessa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2123 holding.
  • Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.